Onward Medical today announced the launch of a capital increase through a private placement worth approximately $47.2 million.
ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities.
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) -- ...
The US Food and Drug Administration (FDA) has granted 510(k) clearance for the expanded use of Onward Medical’s ARC-EX System, now permitting individuals with spinal cord injuries (SCI) to use the ...
Good morning, good afternoon, everyone, and welcome to our ONWARD's webcast following the publication of our results earlier today. As usual, before we get started, please take a moment to read our ...
EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results